Italia markets closed
Dow Jones
38.807,31 +96,02 (+0,25%) Nasdaq
17.187,90 +330,86 (+1,96%) Nikkei 225
38.490,17 -347,29 (-0,89%) EUR/USD
1,0875 -0,0007 (-0,07%) Bitcoin EUR
65.583,48 +768,21 (+1,19%) CMC Crypto 200
1.515,30 +41,56 (+2,82%)
BMY Sep 2024 40.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 10:57AM EDT. Mercato aperto.
| Chiusura precedente | 3,4000 |
| Aperto | 3,0000 |
| Denaro | 3,0500 |
| Domanda | 3,1000 |
| Prezzo d'esercizio | 40,00 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 2,9600 - 3,0000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 680 |
GlobeNewswireArbutus Appoints Two New Executives
Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Chri
© 2024 Yahoo. Tutti i diritti riservati.